Syndax Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, announced the issuance of inducement awards on June 1, 2025, under its 2023 Inducement Plan. The awards allow eight new employees to purchase up to 119,700 shares of common stock. The stock options will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in equal monthly installments over the following 36 months. These terms are contingent on the employees maintaining their service relationship with the company through the respective vesting dates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.